期刊
MEDICAL ONCOLOGY
卷 38, 期 12, 页码 -出版社
HUMANA PRESS INC
DOI: 10.1007/s12032-021-01596-6
关键词
MET; Targeted therapy; Tyrosine kinase inhibitors; Amplification; Resistance
类别
Targeted therapy has revolutionized cancer management, but the development of cancer resistance, particularly through MET activation, poses a major obstacle to its effectiveness. Studies on MET inhibitors for overcoming resistance in solid tumors highlight the need for further research and clinical applications.
Targeted therapy is a hallmark of cancer treatment that has changed the landscape of cancer management and enabled a personalized treatment approach. Nevertheless, the development of cancer resistance is a major challenge that is currently threatening the effective utilization of targeted therapies. The hepatocyte growth factor receptor, MET, is a receptor tyrosine kinase known for its oncogenic activity and tumorigenic potential. MET is a well-known driver of cancer resistance. A growing body of evidence revealed a major role of MET in mediating acquired resistance to several classes of targeted therapies. Deregulations of MET commonly associated with the development of cancer resistance include gene amplification, overexpression, autocrine activation, and crosstalk with other signaling pathways. Small-molecule tyrosine kinase inhibitors of MET are currently approved for the treatment of different solid cancers. This review summarizes the current evidence regarding MET-mediated cancer resistance toward targeted therapies. The molecular mechanisms associated with resistance are described along with findings from preclinical and clinical studies on using MET inhibitors to restore the anticancer activity of targeted therapies for the treatment of solid tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据